{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:02:03Z","timestamp":1777384923087,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.therap.2017.06.002","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T14:15:37Z","timestamp":1501078537000},"page":"691-693","source":"Crossref","is-referenced-by-count":3,"title":["Hyperprolactin\u00e9mie avec galactorrh\u00e9e induites par le lansoprazole\u00a0: \u00e0 propos d\u2019un cas"],"prefix":"10.1016","volume":"72","author":[{"given":"France","family":"Duwicquet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Gras-Champel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Masmoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2017.06.002_bib0055","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.lpm.2012.09.016","article-title":"Effets ind\u00e9sirables \u00e9mergents des inhibiteurs de la pompe \u00e0 protons","volume":"42","author":"Bourne","year":"2013","journal-title":"Presse Med"},{"key":"10.1016\/j.therap.2017.06.002_bib0060","series-title":"Analyse des ventes de m\u00e9dicaments en France en 2013. Communiqu\u00e9s\/points presse","author":"ANSM","year":"2014"},{"key":"10.1016\/j.therap.2017.06.002_bib0065","unstructured":"ANSM. Base de donn\u00e9es publique des m\u00e9dicaments, R\u00e9sum\u00e9 des caract\u00e9ristiques du produit - Lansoprazole Almus 15mg, g\u00e9lules gastro-r\u00e9sistantes. http:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=64911471&typedoc=R [Consult\u00e9 le 23\u00a0juin 2017 (3\u00a0pp) (mise \u00e0 jour 29\/07\/2013)]."},{"key":"10.1016\/j.therap.2017.06.002_bib0070","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.revmed.2011.12.011","article-title":"Effets ind\u00e9sirables des inhibiteurs de la pompe \u00e0 proton\u00a0: faut-il craindre de les prescrire au long cours?","volume":"33","author":"Roulet","year":"2012","journal-title":"Rev Med Int"},{"key":"10.1016\/j.therap.2017.06.002_bib0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2017.06.002_bib0080","first-page":"689","article-title":"Hyperprolactinaemia induced by proton pump inhibitor","volume":"60","author":"Jabbar","year":"2010","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.therap.2017.06.002_bib0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12328-015-0622-7","article-title":"Esomeprazole induced galactorrhea: a novel side effect","volume":"9","author":"Pipaliya","year":"2016","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.therap.2017.06.002_bib0090","unstructured":"ANSM. Base nationale de pharmacovigilance. [Consult\u00e9e le 19\u00a0mai 2017]."},{"key":"10.1016\/j.therap.2017.06.002_bib0095","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450\u00a0activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.therap.2017.06.002_bib0050","first-page":"408","article-title":"Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease","volume":"57","author":"Angl\u00e8s","year":"2002","journal-title":"Therapie"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595717300975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595717300975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T08:14:32Z","timestamp":1554279272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595717300975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0040595717300975"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2017.06.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}